Markets:

Overview

News

Currencies

International

Treasuries

Can-Fite Biopharma Ltd American Depositary Shares (NY:CANF)

4.650 +0.210 (+4.73%)

Official Closing Price Updated: 8:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Can-Fite Biopharma Ltd American Depositary Shares

< Previous 1 2 3 4 Next >

Can-Fite Expects Data Readout From Late-Stage Psoriasis Study With Piclidenoson In Q1 2022 ↗

December 07, 2021

Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last of approximately 400 psoriasis patients enrolled in its Phase 3 Comfort study is scheduled to complete a 16-week...

Via Benzinga

Cannabis-Focused Biotech Company Can-Fite Reports Q3 Financial Results & Clinical Updates ↗

November 26, 2021

Cannabis-focused biotech company Can-Fite BioPharma Ltd. (AMEX:C...

Via Benzinga

Earnings Scheduled For November 26, 2021 ↗

November 26, 2021

Companies Reporting Before The Bell Pinduoduo Inc. (NASDAQ:PDD) is expected to report quarterly earnings at $0.02 per share on revenue of $4.16 billion. BlueCity Holdings Limited...

Via Benzinga

Can-Fite's Kickstarts Piclidenoson Study For Canine Osteoarthritis ↗

November 23, 2021

Can-Fite BioPharma Ltd (NYSE: CANF) has commenced a safety and efficacy study of Piclidenoson to treat osteoarthritis in dogs. Safety results are expected in...

Via Benzinga

Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal ↗

October 21, 2021

PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule...

Via Benzinga

Hope on the Horizon for Liver Cancer Patients as This Company's Namodenoson Drug Starts Pivotal Phase III Global Trial ↗

October 08, 2021

Photo by National Cancer Institute on Unsplash Liver cancer is a growing global health concern. Apart from the financial burden it places on patients and economies, the American...

Via Benzinga

The Week In Cannabis: $1.25B+ In Financings And M&A, Tilray, KushCo, New York And More ↗

August 27, 2021

Below is a recap of the main news related to the cannabis industry and markets for the week of August 27, 2021.

Via Benzinga

Topics Cannabis

Can-Fite Reports Drop In H1 2021 Revenue, Net Loss Down By 38% YoY ↗

August 26, 2021

Biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI) announced its financial results Thursday for the quarter ended June 30, 2021. The Israel-based company...

Via Benzinga

Can-Fite Stock Gains On Piclidenoson Development Pact For Pets ↗

June 28, 2021

Can-Fite BioPharma Ltd (NYSE: CANF) has signed a development and commercialization agreement with France-based veterinary biotech company, Vetbiolix, to...

Via Benzinga

The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test ↗

July 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:...

Via Benzinga

Topics Product Recall

CAN-FITE AHEAD OF SCHEDULE IN ITS FIGHT TO TREAT NASH AND LESSEN THE NEED FOR LIVER TRANSPLANTS ↗

June 03, 2021

Nonalcoholic steatohepatitis (NASH) is the leading cause of disease leading to liver transplants among women and the second-leading cause for liver transplants overall. In...

Via Benzinga

CAN-FITE BIOPHARMA ANNOUNCES ADVANCEMENT OF CLINICAL STUDIES AND NEW EUROPEAN LICENSING AGREEMENTS ↗

May 27, 2021

by Mark Gilman Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI), an Israeli-based biotechnology company advancing a pipeline of proprietary small-molecule drugs that address...

Via Benzinga

The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs ↗

May 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)...

Via Benzinga

CAN-FITE BIOPHARMA GAINS ANALYST "BUY" DISTINCTION AND SIGNS NEW DISTRIBUTION AGREEMENTS FOR ITS LEAD DRUG CANDIDATES ↗

May 12, 2021

Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver...

Via Benzinga

The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx ↗

April 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...

Via Benzinga

Can-Fite Expands Mid-Stage COVID-19 Study To Europe ↗

April 22, 2021

Can-Fite BioPharma Ltd (NYSE: CANF) has expanded its Phase 2 COVID-19 study of Piclidenoson to two European countries, Romania and Bulgaria. The randomized,...

Via Benzinga

Can-Fite Starts Preclinical Studies Required By FDA, EMA For Two Lead Drug Candidates Registration Filing ↗

April 20, 2021

Can-Fite BioPharma (NYSE: CANF) has initiated a series of preclinical studies required by regulators to support potential marketing registration filings for...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Can-Fite Biopharma Ltd American Depositary Shares (NY:CANF)

Headline News about Can-Fite Biopharma Ltd American Depositary Shares

Starting at $3.75/week.

Subscribe Today